SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Swami Vivekananda

PatientVivekananda
Date of birth1991-01-12
IdentifiersMRN HR-NI032-SYN; SSN (made up) 000-32-9014
Document date2026-10-27
AuthorAnjali Thornbury-Mensah, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review after seven months away, a week after an asthma attack. [S]

History of Present Illness

Swami Vivekananda returns a week after the sick visit for a moderate asthma attack, and nine days after coming home from seven months of travel in the mountains. He finished five days of prednisone three days ago; his glucose rose to 210 to 268 mg/dL before the evening meal during the course and came back to 120 to 140 fasting within two days, without other treatment. The nurse telephoned on the second day. He has used the budesonide-formoterol inhaler two to four times a day; he has woken twice in the week with tightness, and the attacks are milder. While away he took metformin 2000 mg, losartan and atorvastatin, messaged his fasting readings (110 to 135 mg/dL), and kept his fortnightly fasts with fruit and milk. He could not find a laboratory for the three-month blood tests, so they were not done. He completed four of six video sessions for insomnia and falls asleep within about 45 minutes on most nights. The festival of the goddess is in two weeks and he intends to keep its fast. [S]

ElementDetail
AsthmaReliever two to four times a day; woken twice in a week; Asthma Control Test 15
Prednisone and glucoseEvening glucose 210 to 268 mg/dL during the course; settled within two days
While awayFasting glucose 110 to 135 mg/dL; three-month laboratory tests not done
SleepFour video sessions of cognitive behavioral therapy for insomnia; about 45 minutes to fall asleep
Coming fastA festival fast in two weeks

Review of Systems

SystemResultFinding
RespiratoryPositiveWheeze and tightness on two nights this week; cough in the mornings
ConstitutionalNegativeEnergy returning; weight 74.8 kg
CardiovascularNegativeNo chest pain or ankle swelling
GenitourinaryNegativeNo nocturia; no urinary symptoms
PsychiatricNegativeCheerful; PHQ-2 1

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin extended-release 500 mg tablets: two tablets (1000 mg) with the evening meal, starting with one for the first week1000 mg with the evening mealOral route2026-02-16 to 2026-03-23completedS
Metformin extended-release 500 mg tablets: four tablets (2000 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink2000 mg with the evening mealOral route2026-03-23activeS
Losartan 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-09activeS
Atorvastatin 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Prednisone 20 mg oral tablet, two tablets (40 mg) each morning for five days40 mg each morning for five daysOral route2026-10-20 to 2026-10-24completedS
Budesonide-formoterol 160/4.5 mcg inhaler with a spacer, one inhalation as needed for wheeze or breathlessness, no more than 12 inhalations a day, until lung function testingOne inhalation as neededRespiratory tract route2026-10-20 to 2026-10-27completedS
Empagliflozin 10 mg oral tablet, one tablet each morning; skip it on any day of fasting without water, and stop it when unable to eat or drinkOne tablet dailyOral route2026-10-27activeS
Budesonide-formoterol 160/4.5 mcg inhaler with a spacer as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one as needed, no more than 12 inhalations a dayOne inhalation twice daily plus one as neededRespiratory tract route2026-10-27activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-27Body height172cmS
2026-10-27Body weight74.8kgS
2026-10-27Body mass index (BMI) [Ratio]25.3kg/m2S
2026-10-27Systolic blood pressure126mm[Hg]S
2026-10-27Diastolic blood pressure78mm[Hg]S
2026-10-27Heart rate82/minS
2026-10-27Respiratory rate16/minS
2026-10-27Body temperature36.6CelS
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-27Hemoglobin A1c/Hemoglobin.total in Blood6.9%Below 5.7% is normal; 6.5% or more diabetes; his target below 7%HighS
2026-10-27Glucose [Mass/volume] in Serum or Plasma124mg/dLFasting; 126 mg/dL or more indicates diabetesHighS
2026-10-27Albumin/Creatinine [Mass Ratio] in Urine34mg/g30 to 299 moderately increased; 300 or more severely increasedHighS
2026-10-27Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-10-27Creatinine [Mass/volume] in Serum or Plasma0.98mg/dL0.74-1.35 mg/dLNormalS
2026-10-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M103mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-27Cholesterol [Mass/volume] in Serum or Plasma152mg/dL<=199 mg/dLNormalS
2026-10-27Cholesterol in HDL [Mass/volume] in Serum or Plasma39mg/dL40 mg/dL or more for menLowS
2026-10-27Triglyceride [Mass/volume] in Serum or Plasma146mg/dL<=149 mg/dLNormalS
2026-10-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation84mg/dL<=99 mg/dLNormalS
2026-10-27FEV1 --pre bronchodilation2.95LLower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations)LowS
2026-10-27FEV1 --post bronchodilation3.42LLower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations)NormalS
2026-10-27FEV1 measured/predicted77%GLI Global race-neutral equationsLowS
2026-10-27FEV1/FVC0.66{ratio}Lower limit of normal for his age (GLI Global)LowS
2026-10-27FEV1/FVC --post bronchodilation0.75{ratio}Lower limit of normal for his age (GLI Global)NormalS
2026-10-27Fractional concentration of exhaled nitric oxide44[ppb]Above 50 ppb high; 25 to 50 intermediate (ATS)HighS
2026-10-27Total score [ACT]15{score}S
2026-10-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 74.8 kg, BMI 25.3; blood pressure 126/78, pulse 82; oxygen saturation 97 percent
RespiratoryFaint expiratory wheeze on forced expiration
CardiovascularRegular; no edema
FeetSkin intact after months of walking; no calluses or sores

Problems

ProblemClinical statusVerificationCodeProvenance
Thirst, frequent urination day and night, tiredness and about 4 kg weight loss over two months, with a random glucose of 246 mg/dL; told by physicians a year ago that he had diabetes, never confirmed with modern tests or treated except by diet. Diabetes to be confirmed and classified (type 2, type 1 or slowly progressive autoimmune diabetes) with A1c, fasting glucose, GAD antibodies and C-peptideresolvedconfirmed R73.9S — Synthetic presenting problem anchored to his documented diabetes of the year before. Superseded by the diagnosis at the second visit.
Type 2 diabetes: A1c 9.4 percent and fasting glucose 172 mg/dL, with symptoms; GAD65 antibodies negative and fasting C-peptide preserved (2.6 ng/mL); no ketones. BMI 24.6, in the range where ADA screens Asian Americans. Classified as type 2, not type 1 or slowly progressive autoimmune diabetesactiveconfirmed E11.65S — Synthetic modern confirmation and classification linked to his documented diabetes.
Moderately increased albuminuria on a first sample (urine albumin-to-creatinine ratio 46 mg/g), eGFR normal; to be confirmed on two of three samples over three to six monthsresolvedconfirmed R80.9S — Synthetic finding linked to his documented albuminuria; superseded when diabetic kidney disease was confirmed.
Raised blood pressure in clinic (138/86, average of two readings) without a diagnosis of hypertension; home readings to be takenresolvedconfirmed R03.0S — Synthetic finding; not a claim about his real blood pressure.
Hypertension, stage 1: clinic 138/86, 136/86 and 134/84; home average 136/86 over seven days; with moderately increased albuminuria and diabetesactiveconfirmed I10S — Synthetic finding of the modern episode; not a claim about his real blood pressure, which was never recorded.
Long-standing difficulty falling asleep: by his own account he has never been able to fall asleep on getting into bed and lies awake for two hours or more most nights; worse lately with waking to pass urine; rises before dawn for meditationactiveconfirmed G47.00S — Synthetic modern problem linked to his documented lifelong difficulty falling asleep.
Mixed hyperlipidemia: LDL cholesterol 132 mg/dL, triglycerides 228, HDL 36activeconfirmed E78.2S — Synthetic cardiovascular risk factor.
Attacks of wheeze and breathlessness for three weeks since coming down from the mountains to the damp plains, the worst last night with a sense of suffocation: peak flow 330 L/min (56 percent of predicted), oxygen saturation 94 percent, rising to 410 L/min after bronchodilator; no fever, edema or chest pain; chest X-ray and ECG without heart failure or pneumonia. Asthma to be confirmed with spirometryresolvedconfirmed R06.2S — Synthetic presenting problem anchored to his documented suffocating attacks of asthma on his return to Belur. Superseded by the diagnosis a week later.
Asthma, adult onset, confirmed: FEV1 2.95 L (77 percent predicted) rising 470 mL (16 percent) after bronchodilator, FEV1/FVC 0.66 rising to 0.75; FeNO 44 ppb; brought on by damp air and smoke; one moderate attack treated with prednisoneactiveconfirmed J45.40S — Synthetic modern confirmation linked to his documented attacks of asthma.
Diabetic kidney disease, CKD stage G1 A2: moderately increased albuminuria on three samples over eight months (46, 41 and 34 mg/g) with eGFR above 90activeconfirmed E11.21S — Synthetic modern diagnosis linked to his documented albuminuria and Bright's disease; not a claim about the cause of his real kidney disease.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryA1cQuarterly until at goal and after a change in therapyCompleted today6.9 percent, at target
LaboratoryA1c three months after the change in therapyQuarterly after a change in therapyDeferredMissed: due three months after the metformin dose increase, while he was travelling in the mountains, and he could not find a laboratory. No harm resulted judging by today's A1c of 6.9 percent and his monthly fasting readings of 110 to 135 mg/dL. Corrective action: a point-of-care or mail-in A1c kit and a video visit are now arranged before any journey longer than two months
LaboratoryUrine albumin-to-creatinine ratio, eGFR and potassiumTo confirm albuminuria; then every six months at G1 A2; potassium on an ARBCompleted today34 mg/g, the third abnormal sample (46, 41, 34): diabetic kidney disease confirmed; eGFR 103; potassium 4.5
LaboratoryLipid panel after starting a statinFour to twelve weeks after startingDeferredMissed: due six to twelve weeks after starting atorvastatin, during his travels; done today, seven months after starting: LDL 84, triglycerides 146. No harm resulted. Corrective action: as for the A1c, testing before long journeys is now planned
ExaminationBlood pressure, weight and BMIEvery visitCompleted today126/78; weight 74.8 kg, BMI 25.3
ExaminationFoot examinationYearly; inspection after long walkingCompleted todayIntact; no calluses or sores
Medication safetySGLT2 inhibitor safety: fasting, illness, genital infection and volumeAt start and every visitCompleted todayFasting and sick-day rules given; genital hygiene advice; blood pressure 126/78; no orthostatic symptoms
Medication safetyGlucose during oral corticosteroidsDuring any steroid courseCompleted todayEvening glucose 210 to 268 mg/dL during prednisone; settled without insulin
Self-managementFasting planBefore any religious fastCompleted todayPlan for the festival fast in two weeks with empagliflozin and metformin
ImagingSpirometry with bronchodilator response and FeNOAt diagnosis of asthmaCompleted todayFEV1 2.95 L (77 percent) to 3.42 L (+470 mL, +16 percent); FEV1/FVC 0.66 to 0.75; FeNO 44 ppb
SurveyAsthma Control Test, symptoms, night waking and reliever useEvery visitCompleted todayAsthma Control Test 15; woken twice this week; reliever two to four times a day
Self-managementReview within a week of an exacerbationWithin one to seven days after any exacerbationCompleted todayNurse call on day two; this review on day seven
ExaminationInhaler technique and action planEvery visitCompleted todayTechnique correct with a spacer; written plan given
SurveyDepression screenYearly and as neededCompleted todayPHQ-2 1
Self-managementVaccinationsYearlyCompleted todayInfluenza and COVID-19 for the new season; hepatitis B dose 2, delayed by his travel, completes the series
Self-managementInsomnia treatmentUntil the course is completeCompleted todayFour of six sessions done; sleep onset about 45 minutes

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Influenza vaccine, the new season; COVID-19 mRNA vaccine, the new season's formula [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, CKD and asthma monographs (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); Hassanein M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract 2022;185:109185 (PMID 35016991) (2021); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023)

Follow-up: Asthma review in four to six weeks. Diabetes and kidney review with A1c, potassium, creatinine and urine albumin in three months. Call during the festival fast if glucose is below 70 or above 300 mg/dL. Next preventive visit in the spring. [S]